Skip to main content
. 2024 Dec 21;15:495. doi: 10.1186/s13287-024-04103-6

Fig. 2.

Fig. 2

Estimated OS (a) and TFS (b) for thalassemia patients receiving UD-HSCT and the OS (c) and TFS (d) for patients receiving MSD-HSCT in the NCR and CCR groups